ATyr Pharma Surges 40% On Positive Data From Pulmonary Sarcoidosis Drug Trial

Shares of aTyr Pharma, Inc. (LIFE) are gaining nearly 40% on Monday after the clinical-stage biotherapeutics company and its Hong Kong Subsidiary, Pangu BioPharma, announced positive data from a phase 1b/2a clinical trial demonstrating consistent dose response of ATYR1923 in pulmonary sarcoidosis.

LIFE is currently trading at $7.56, up $2.08 or 38.03%, on the Nasdaq, on a volume of 39.7 million shares, far above the average volume of 181 thousand. The stock has traded between $2.93 to $8.33 per share in the past 52-week period. The stock's value has more than doubled in that time frame.

According to the company, ATYR1923 was safe and well-tolerated at all doses with no drug-related serious adverse events or signal of immunogenicity.

Pulmonary sarcoidosis is an inflammatory disease characterized by the formulation of granulomas, clumps of inflammatory cells, in one or more organs of the body. Approximately 200,000 Americans live with pulmonary sarcoidosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT